HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE COVER ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a letter to the editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, B. Search for Related Content PubMed PubMed Citation Articles by Fisher, B.

CA: A Cancer Journal for Clinicians, Vol 49, Issue 3 159-177, Copyright © 1999 by American Cancer Society

ARTICLES

Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer

B. Fisher
Allegheny University of the Health Sciences, Pittsburgh, USA.

Findings from major National Surgical Adjuvant Breast and Bowel Project studies in women with breast cancer and negative axillary nodes are reported and discussed. Results of the B-13 and B-19 studies demonstrated that systemic chemotherapy (either with methotrexate and sequentially administered fluorouracil followed by leucovorin, or with cyclophosphamide plus methotrexate and fluorouracil) increased overall disease-free survival in women 49 years of age or younger, as well as in those 50 years old or older. Women older than 50 also experienced a survival advantage with chemotherapy. Moreover, women who received systemic chemotherapy after lumpectomy plus radiation therapy were significantly less likely to develop an ipsilateral recurrence of tumor. The B-14 study established the benefit of tamoxifen. When chemotherapy was added to tamoxifen in the B-20 trial, there was an increased benefit. The B-18 trial demonstrated that the outcome of patients who received preoperative chemotherapy was comparable to that of patients who received the same therapy postoperatively. Moreover, results suggested that breast tumor response to preoperative chemotherapy correlated with outcome. Also, larger tumors were sufficiently downstaged by preoperative chemotherapy to permit lumpectomy rather than mastectomy. The B-17 study in women with ductal carcinoma in situ concluded that radiation therapy should follow lumpectomy in women with localized, mammographically detected lesions. The P-1 Breast Cancer Prevention trial showed that tamoxifen was effective in significantly reducing the incidence of both invasive and noninvasive breast tumors in women at high risk for the disease. Although many questions remain, and a new study, P-2, has been designed to compare tamoxifen and raloxifene, it is appropriate to offer tamoxifen to women who are similar to those in the P-1 study and who may benefit from it.

This article has been cited by other articles:

				B. S. Schaffer, C. M. Lachel, K. L. Pennington, C. R. Murrin, T. E. Strecker, M. Tochacek, K. A. Gould, J. L. Meza, R. D. McComb, and J. D. Shull Genetic Bases of Estrogen-Induced Tumorigenesis in the Rat: Mapping of Loci Controlling Susceptibility to Mammary Cancer in a Brown Norway x ACI Intercross. Cancer Res., August 1, 2006; 66(15): 7793 - 7800. [Abstract] [Full Text] [PDF]

				R. Taylor and K. Taguchi Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump Ann. Fam. Med, May 1, 2005; 3(3): 242 - 247. [Abstract] [Full Text] [PDF]

				B. Fisher, J.-H. Jeong, S. Anderson, and N. Wolmark Treatment of Axillary Lymph Node-Negative, Estrogen Receptor-Negative Breast Cancer: Updated Findings From National Surgical Adjuvant Breast and Bowel Project Clinical Trials J Natl Cancer Inst, December 15, 2004; 96(24): 1823 - 1831. [Abstract] [Full Text] [PDF]

				E. R. Sauter, L. Schlatter, J. Hewett, D. Koivunen, and J. T. Flynn Lack of Effect of Celecoxib on Prostaglandin E2 Concentrations in Nipple Aspirate Fluid from Women at Increased Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1745 - 1750. [Abstract] [Full Text] [PDF]

				X. L. Du, C. R. Key, C. Osborne, J. D. Mahnken, and J. S. Goodwin Discrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer Ann Intern Med, January 21, 2003; 138(2): 90 - 97. [Abstract] [Full Text] [PDF]

				X. L. Du, C. Osborne, and J. S. Goodwin Population-Based Assessment of Hospitalizations for Toxicity From Chemotherapy in Older Women With Breast Cancer J. Clin. Oncol., December 15, 2002; 20(24): 4636 - 4642. [Abstract] [Full Text] [PDF]

				R. L. Divi, Y. P. Dragan, H. C. Pitot, and M. C. Poirier Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen Carcinogenesis, October 1, 2001; 22(10): 1693 - 1699. [Abstract] [Full Text] [PDF]

				C. C. Wykoff, N. Beasley, P. H. Watson, L. Campo, S. K. Chia, R. English, J. Pastorek, W. S. Sly, P. Ratcliffe, and A. L. Harris Expression of the Hypoxia-Inducible and Tumor-Associated Carbonic Anhydrases in Ductal Carcinoma in Situ of the Breast Am. J. Pathol., March 1, 2001; 158(3): 1011 - 1019. [Abstract] [Full Text] [PDF]